Skip to main content

Advertisement

SpringerLink
Log in

Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the significance of carbohydrate antigen 19-9 (CA19-9) levels for survival in locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT).

Methods/patients

We retrospectively reviewed data from 97 LAPC patients treated with CCRT between 2000 and 2013. CA19-9 levels (initial and post-CCRT) and their changes [{(post-CCRT CA19-9 level − initial CA19-9 level)/(initial CA19-9 level)} × 100] were analyzed for overall survival. A cut-off point of 37 U/mL was used to analyze initial and post-CCRT CA19-9 levels. In order to define an optimal cut-off point for change in CA19-9 level, the maxstat package of R was applied.

Results

Median overall survival was 14.7 months (95% CI 13.4–16.0), and the 2-year survival rate was 16.5%. The estimated optimal cut-off point of CA19-9 level change was 94.4%. On univariate analyses, CA19-9 level change between initial and post-CCRT was significantly correlated with overall survival (median survival time 9.7 vs 16.3 months, p < 0.001). Multivariate analyses confirmed that CA19-9 level change from initial to post-CCRT was the only prognostic factor (p < 0.001).

Conclusions

Change in CA19-9 level between initial and post-CCRT was a significant prognostic marker for overall survival in LAPC treated with CCRT. A CA19-9 level increase >94.4% might serve as a surrogate marker for poor survival in patients with LAPC undergoing CCRT, and the prognostic power surpassed other CA19-9 variables including initial and post-CCRT values.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Koprowski H, Steplewski Z, Mitchell K et al (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–971

    Article  CAS  PubMed  Google Scholar 

  2. Haas M, Heinemann V, Kullmann F et al (2013) Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 139:681–689

    Article  CAS  PubMed  Google Scholar 

  3. Bauer TM, El-Rayes BF, Li X et al (2013) Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. Cancer 119:285–292

    Article  CAS  PubMed  Google Scholar 

  4. Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107:15–22

    Article  PubMed  Google Scholar 

  5. Bergquist JR, Puig CA, Shubert CR et al (2016) Carbohydrate antigen 19-9 elevation in anatomically resectable, early-stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study. J Am Coll Surg 223:52–65

    Article  PubMed  Google Scholar 

  6. Nazli O, Bozdag AD, Tansug T et al (2000) The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepato-gastroenterology 47:1750–1752

    CAS  PubMed  Google Scholar 

  7. Ni XG, Bai XF, Mao YL et al (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31:164–169

    Article  CAS  PubMed  Google Scholar 

  8. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–270

    Article  CAS  PubMed  Google Scholar 

  9. Poruk EK, Gay DZ, Brown K et al (2013) The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13:340–351

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Schlieman MG, Ho HS, Bold RJ (2003) Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 138:951–956

    Article  PubMed  Google Scholar 

  11. Kondo N, Murakami Y, Uemura K et al (2010) Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 17:2321–2329

    Article  PubMed  Google Scholar 

  12. Boone BA, Steve J, Zenati MS et al (2014) Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 21:4351–4358

    Article  PubMed  Google Scholar 

  13. Tzeng CW, Balachandran A, Ahmad M et al (2014) Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16:430–438

    Article  Google Scholar 

  14. Ballehaninna UK, Chamberlain RS (2011) Serum CA 19-9 as a biomarker for pancreatic cancer − a comprehensive review. Indian J Surg Oncol 2:88–100

    Article  PubMed  PubMed Central  Google Scholar 

  15. Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327

    Article  CAS  PubMed  Google Scholar 

  16. Mattes MD, Cardinal JS, Jacobson GM (2016) Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer. Radiat Oncol J 34:156–159

    Article  PubMed  PubMed Central  Google Scholar 

  17. Berger AC, Garcia M, Hoffman JP et al (2008) Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26:5918–5922

    Article  PubMed  PubMed Central  Google Scholar 

  18. Vainshtein JM, Schipper M, Zalupski MM et al (2013) Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. Int J Radiat Oncol Biol Phys 86:96–101

    Article  CAS  PubMed  Google Scholar 

  19. Koom WS, Seong J, Kim YB et al (2009) CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 73:1148–1154

    Article  CAS  PubMed  Google Scholar 

  20. Lausen B, Schumacher M (1992) Maximally selected rank statistics. Biometrics 48:73–85

    Article  Google Scholar 

  21. Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277

    Article  CAS  PubMed  Google Scholar 

  22. Shaib WL, Ip A, Cardona K et al (2016) Contemporary management of borderline resectable and locally advanced unresectable pancreatic cancer. Oncologist 21:178–187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Huguet F, Andre T, Hammel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331

    Article  CAS  PubMed  Google Scholar 

  24. Hammel P, Huguet F, van Laethem JL et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853

    Article  CAS  PubMed  Google Scholar 

  25. Choi Y, Oh DY, Kim K et al (2015) Concurrent chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study. Cancer Res Treat 48:1045–1055

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chen Y, Sun XJ, Jiang TH et al (2013) Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol 19:7461–7471

    Article  PubMed  PubMed Central  Google Scholar 

  27. Arvold ND, Ryan DP, Niemierko A et al (2012) Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 118:3026–3035

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Yi-Jun Kim and Hyeon Kang Koh contributed equally to this study.

Authors and Affiliations

  1. Department of Radiation Oncology, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul, 07985, Republic of Korea

    Yi-Jun Kim & Kyubo Kim

  2. Department of Radiation Oncology, Konkuk University School of Medicine, Seoul, Republic of Korea

    Hyeon Kang Koh

  3. Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea

    Eui Kyu Chie

  4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    Do-Youn Oh & Yung-Jue Bang

  5. Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Republic of Korea

    Eun Mi Nam

Authors
  1. Yi-Jun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyeon Kang Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eui Kyu Chie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Do-Youn Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yung-Jue Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eun Mi Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kyubo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Eui Kyu Chie or Kyubo Kim.

Ethics declarations

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 20 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, YJ., Koh, H.K., Chie, E.K. et al. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy . Int J Clin Oncol 22, 1069–1075 (2017). https://doi.org/10.1007/s10147-017-1129-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1129-7

Keywords

Search

Navigation